Eli Lilly: study with UnitedHealth in Covid-19
(CercleFinance.com) - Eli Lilly has announced that it is partnering with UnitedHealth Group to conduct a pragmatic study of its neutralizing antibody bamlanivimab (LY-CoV555) in high-risk Covid-19 infected people.
bamlanivimab recently received emergency approval from the US FDA for use in patients with mild-to-moderate Covid-19 with a high risk of disease progression to severe disease and/or hospitalization.
The trial will evaluate the efficacy and safety of the product in individuals meeting the criteria for this authorization. It will combine daily symptom monitoring, as well as SARS-CoV-2 testing and home infusion services.
The share is up over 2.5% an hour into trading on Friday in New York.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
bamlanivimab recently received emergency approval from the US FDA for use in patients with mild-to-moderate Covid-19 with a high risk of disease progression to severe disease and/or hospitalization.
The trial will evaluate the efficacy and safety of the product in individuals meeting the criteria for this authorization. It will combine daily symptom monitoring, as well as SARS-CoV-2 testing and home infusion services.
The share is up over 2.5% an hour into trading on Friday in New York.
Copyright (c) 2020 CercleFinance.com. All rights reserved.